Analysts Predict Upside for John Hancock Multifactor ETF

Analysts forecast a 12.34% upside for John Hancock Multifactor Mid Cap ETF (JHMM) based on its underlying holdings. Key stocks like Revolution Medicines (RVMD) show significant potential upside, indicating a positive outlook for investors.

Date: 30-01-2025

AI Rating: 7

Overview of Analyst Predictions

The report reveals promising potential for the John Hancock Multifactor Mid Cap ETF (JHMM) with a calculated upside of 12.34%. The ETF recently traded at $62.34, while analysts predict a target price of $70.03. This positive outlook can stimulate interest from investors seeking potential growth.

Underlying Holdings

Several underlying holdings within JHMM exhibit notable upside potential. Revolution Medicines Inc (RVMD) trades at $40.92, yet the average analyst target stands at $73.43, implying a remarkable upside of 79.44%. Conversely, Vaxcyte Inc (PCVX) presents a 65.28% upside with a recent price of $88.67 compared to a target of $146.56. Additionally, Summit Therapeutics Inc (SMMT) is perceived to have a potential increase of 55.13%, trading currently at $21.64 with a target of $33.57. These significant potential returns could attract investor interest, potentially moving stock prices higher as market sentiment shifts positively.

Market Sentiment

A high target price relative to current trading prices often reflects optimism. However, it also raises questions about the validity of these targets in light of recent developments. While the predicted upsides are substantial, whether analysts remain justified in their targets amidst changing market conditions remains to be seen. Investors may need to conduct further research to gauge the sustainability of these projections.

Stocks: JHMM RVMD PCVX SMMT